Big Pharma Tightens Its Belt in Global Manufacturing
In the aftermath of recent restructuring, Big Pharma is sporting a reduced global manufacturing footprint while intensifying its focus to biologics and emerging markets. What will be the look of tomorrow's manufacturing networks?
Aug 02, 2009
Volume 33, Issue 8